Should You Buy Castle Biosciences, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Castle Biosciences, Inc. (CSTL) occupies a solid middle-ground position with a Quality of Company score of 7.3/10. At the current market price of $35.50, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 1 of 5 CirclFi valuation models project upside for Castle Biosciences, Inc. (CSTL) at $35.50 — the model consensus leans bearish, with a Quality Score of 7.3/10 and Value-Trap risk of 6/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
What Is the Investment Case for Castle Biosciences, Inc. (CSTL) in 2026?
What Is the Bull Case vs the Bear Case for Castle Biosciences, Inc. (CSTL)?
| Bull case — $37.18 target (+4.7%) | Bear case — $4.31 target (-87.9%) |
|---|---|
| According to the CirclFi Quality of Company (QOC) framework, Castle Biosciences, Inc.'s score of 7.3/10 reflects durable competitive advantages that should sustain earnings power through market cycles. | According to the CirclFi Deep Alpha Valuation Engine, the Bayesian DCF model sees the stock as overvalued with a fair value of $4.31 (-87.9%), suggesting that the market price embeds overly optimistic growth assumptions. |
| Industry tailwind: therapeutic area leadership could provide meaningful support for Castle Biosciences, Inc.'s revenue and margin trajectory in the Diagnostics & Research space. | According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +92.6% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology. |
| Industry headwind: drug pricing legislation represents a meaningful risk for Castle Biosciences, Inc. and its Diagnostics & Research peers. |
How Does CSTL Compare to Its Diagnostics & Research Peers?
Valuation data pages: NTRA · CDNA · RVTY · ADPT · LDDD · GH · WGS · PRPH · MTD · IDXX · MEDP
Which Other Stocks Score Like CSTL on Quality?
Closest companies to CSTL’s Quality of Company score of 7.3/10, across all industries.
- ASLE — AerSale Corporation (QOC 7.3) · analysis
- GTLB — GitLab Inc. (QOC 7.3) · analysis
- FISK — Empire State Realty OP, L.P. (QOC 7.3) · analysis
- CVI — CVR Energy, Inc. (QOC 7.3) · analysis
- HKHC — Horizon Kinetics Holding Corporation (QOC 7.3) · analysis
- VREX — Varex Imaging Corporation (QOC 7.3) · analysis
- NVDA — NVIDIA Corporation (QOC 10.0) · analysis
So Is Castle Biosciences, Inc. (CSTL) Worth Buying in 2026?
Our valuation engine sends a clear cautionary signal on Castle Biosciences, Inc. at $35.50. 4/5 models flag overvaluation, median fair value sits at $9.22 (-74.0%), and the risk-reward profile appears unfavorable. Quality at 7.3/10 is the one bright spot, but premium quality at the wrong price can still destroy returns. This is a stock where patience — or avoidance — may be the optimal strategy.
These are quantitative model outputs, not investment recommendations. Castle Biosciences, Inc.'s future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
What Else Do Investors Ask About CSTL Stock?
Should I buy CSTL stock right now?
Based on CirclFi's multi-model analysis, 1 of 5 models see upside for CSTL at $35.50. The models are divided, which means the investment case depends heavily on your assumptions about Castle Biosciences, Inc.'s future. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Castle Biosciences, Inc.?
Key risks include: limited model coverage (5/13 active), reducing analytical confidence; wide model disagreement (763% spread), signaling high uncertainty; general market and sector-specific risks affecting Diagnostics & Research companies. Always diversify and consult a financial advisor.
How does CSTL compare to its competitors?
Among Diagnostics & Research peers, CSTL holds a Quality Score of 7.3/10. Comparable companies include NTRA (QOC 7.4), CDNA (QOC 7.3), RVTY (QOC 7.5). The relative ranking helps investors identify whether CSTL offers better fundamental quality than alternatives in the same sector.
Is CSTL a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. CSTL's Quality Score of 7.3/10 is encouraging for long-term holders, indicating consistent profitability, manageable debt, and healthy cash flows. Check our full data page for all 13 model estimates.
What price should I buy CSTL at?
CirclFi does not provide target buy prices or price alerts. However, our 5 active models produce fair value estimates ranging from $4.31 to $37.18. At $35.50, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for CSTL.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad